<DOC>
	<DOCNO>NCT00570778</DOCNO>
	<brief_summary>This study evaluate safety efficacy QVA149 patient moderate severe COPD .</brief_summary>
	<brief_title>Efficacy Safety QVA149 Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>1 . Male female adult age ≥40 year , sign Informed Consent Form prior initiation studyrelated procedure . 2 . Patients moderate severe stable Chronic Obstructive Pulmonary Disease ( COPD ) accord Global Initiative Obstructive Lung Disease ( GOLD ) Guidelines 2006 . 3 . Patients smoke history least 10 pack year . 4 . Patients postbronchodilator Forced Expiratory Volume 1 second ( FEV1 ) ≥30 % &lt; 80 % predict normal postbronchodilator FEV1/Forced Vital Capacity ( FVC ) &lt; 0.70 . 1 . Pregnant nursing woman , woman childbearing potential , regardless whether sexually active use acceptable method contraception . 2 . Patients require long term oxygen therapy ( &gt; 15 hour day ) daily basis chronic hypoxemia , hospitalize visited emergency department COPD exacerbation result airways disease 6 week prior screen . 3 . Patients respiratory tract infection within 6 week prior screen . 4 . Patients concomitant pulmonary disease , pulmonary tuberculosis ( unless confirm chest xray longer active ) clinically significant bronchiectasis . 5 . Patients history asthma indicate ( limited ) blood eosinophil count &gt; 400/mm3 . 6 . Patients , judgment investigator responsible Novartis personnel , clinically relevant laboratory abnormality clinically significant condition . 7 . Patients uncontrolled Type I Type II diabetes . 8 . History malignancy organ system ( include lung cancer ) , treat untreated , within past 5 year . 9 . Patients contraindicate show untoward reaction inhale anticholinergic agent . 10 . Patients history long QT syndrome whose QTc interval ( Fridericia method ) measure screen prolong ( &gt; 450 m male &gt; 470 ms female ) . 11 . Patients history untoward reaction sympathomimetic amine , inhaled medication component thereof , study drug drug similar chemical structure . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>QVA , Indacaterol , Glycopyrrolate , Concept1 , COPD , cross study , safety efficacy , trough FEV1</keyword>
</DOC>